Figure 5. Vactosertib inhibits late stage of pulmonary metastasis in vivo.

A) Experimental design of advanced stage of metastatic OS. BALB/c mice were inoculated with 1×10⁶ K7M2-Luc (i.v.) on day 0, and then treated with vehicle (p.o) or Vactosertib (50 mg/kg, p.o. 5 days/week) starting on day 28 (4 weeks). B) Bioluminescence image intensity was measured once a week. Graph of BLI over time. n=5, **p<0.01 using a two-way ANOVA between groups followed by post-hoc Tukey’s multiple comparison tests. C) Representative BLI images of vehicle or Vactosertib treated mice at 4 weeks and 10 weeks after tumor injection. D) Representative H & E staining of lung from mice treated with vehicle or Vactosertib 10 weeks after tumor cell injection. Scale bar = 5 mm. E) Relative mRNA expressions of GP70 in the lung samples of vehicle or Vactosertib treated tumor bearing mice compared with that of healthy mice. n=4–5/group, *p<0.05 using an unpaired two-tailed t-test.